. Author manuscript; available in PMC: 2020 Apr 11.

Published in final edited form as: J Med Chem. 2019 Mar 22;62(7):3503–3512. doi: 10.1021/acs.jmedchem.8b01972

Table 3.

In vivo efficacy of pyrrolidine 54b in P. chabaudi ASCQ infected mice.

Oral Dose (qd)	% Inh. of Growth	Plasma Compound Concentration (nM)
Oral Dose (qd)	% Inh. of Growth	1h	6h	24 h
54b, 3 mg/kg/day	22.4 ± 11.6	640	140	0
54b, 10 mg/kg/day	75.2 ± 10.6	1,160	960	10
54b, 30 mg/kg/day	98.7 ± 0.2	2,150	1,630	110
CQ, 10 mg/kg/day	95.0 ± 1.1	-	-	-

Inhibition of parasitemia after 4 days of qd oral dosing and plasma compound concentrations on Day 4. n=6 animals/group.